Here's why Pfizer stock is still a buy

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

Pfizer Reshapes Portfolio With Obesity Bet, Vaccine Deal And Pricing Shift

Pfizer (NYSE:PFE) agreed to acquire weight loss drug developer Metsera for US$10b, entering the obesity and GLP-1 market. The company signed a licensing deal with Novavax for access to its Matrix-M ...

Pfizer Balances Vaccine Expansion And Drug Discounts With Novavax And TrumpRx

Pfizer (NYSE:PFE) has entered a non exclusive licensing agreement with Novavax for access to its Matrix-M adjuvant technology. The company is also participating in the White House TrumpRx initiative, ...

‘We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post-COVID bet on oncology

"The winners in life are differentiated from the losers in life because the winners never fall," Albert Bourla says. "The ...

7 Companies Owned by Pfizer

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...